GenomeDx Biosciences Announces data on genomic tests for prostate and bladder cancer to be presented at the annual meeting of UAE

SAN DIEGO, 11 April 2014/PRNewswire /-GenomeDx Biosciences announced today two study abstracts for Genomic analysis of the company for the prostate and bladder cancers have been chosen as "Best posters in a Poster Session" by the organizers of the Conference in the annual European Congress 29 Association of Urology.

The first presentation of poster shows the clinical validation of decipher sorter ® for prostate cancer for the prediction of failure of treatment in men treated with radiation therapy after surgery.  The second poster presentation, reports on the discovery and validation of a genomic signature 15-marker to predict recurrence of high-risk bladder cancer.

Follow the timetable for the presentation of posters in UAE:

Session title: "Improvement in the measurement of biomarkers in prostate cancer"
Overview of title: "Validation of a classifier of genomic for prediction of biochemical failure after postoperative radiotherapy in high-risk prostate cancer"
Date and time: Saturday, April 12, 2014, 16:00 to 17:30 UTC
Room: A2
Abstract #: 205

Session title: "Modern staging in bladder and upper tract urothelial carcinomas: a new era has begun"
Overview of title: "Discovery and validation of a signature of novel expression for prediction of recurrence in subsequent cystectomy of high-risk bladder cancer"
Date and time: Monday, April 14, 2014, 12:15 to 13:45 UTC
Room: K1
Abstract #: 898

About GenomeDx Biosciences
GenomeDx Biosciences develops and markets Genomic analysis for prostate and other Urologic Cancers that impact treatment decisions, improve patient outcomes and ultimately reduce health care costs. GenomeDx has developed the decoding of prostate cancer classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer regardless of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. www.genomedx.com

Press contact:
Cammy Duong
Canale communications
619-849-5382
Cammy@canalecomm.com

SOURCE GenomeDx Biosciences

RELATED LINKS
http://www.genomedx.com